Drugs / tirilizumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06470217 | Jun 2024 → Jun 2025 overdue | head and neck squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tirilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06470217 ↗ |
| Route | Intravenous | “tirilizumab administered by intravenous drip” NCT06470217 ↗ |